

Access through your institution





Get Access

Share

**Export** 

# Digestive and Liver Disease

Volume 49, Issue 1, January 2017, Pages 11-16

#### Alimentary Tract

Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis

Anne-Claire Frin  $^{a, 1}$ , Jérôme Filippi  $^{a, 1}$ , Gilles Boschetti  $^{b}$ , Bernard Flourie  $^{b}$ , Jocelyne Drai  $^{c}$ , Patricia Ferrari  $^{d}$ , Xavier Hebuterne  $^{a}$ , Stéphane Nancey  $^{b} \stackrel{\boxtimes}{\sim} \boxtimes$ 

- <sup>a</sup> Department of Gastroenterology, Centre Hospitalier Universitaire L'Archet, Nice, France
- b Department of Gastroenterology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France & INSERM U1111, International Center for Research in Infectiology, Lyon, France
- <sup>c</sup> Laboratory of Biochemistry, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France
- d Laboratory of Biochemistry, Centre Hospitalier Universitaire Pasteur, Nice, France

Received 11 August 2016, Accepted 3 September 2016, Available online 13 September 2016.





https://doi.org/10.1016/j.dld.2016.09.001

Get rights and content

### **Abstract**

## Background

Fecal markers might predict the response to anti-TNF $\alpha$  in ulcerative colitis (UC).

#### Aims

To compare the performance of fecal calprotectin (fCal), lactoferrin (fLact), M2-PK (fM2-PK), neopterin (fNeo), and zonulin (fZon) to predict the response to therapy in active UC patients.

### Methods

Disease activity from 31 consecutive patients with an active UC, treated with infliximab (IFX) was assessed by the Mayo score at baseline and at week 14 and by the partial Mayo score at W52 and stool samples collected for fecal marker measurements at W0, W2, and W14.

## Results

At W14, 19 patients (61%) were responders to IFX induction. The median levels of fCal, fLact and fM2-PK drop dramatically from baseline to W14 in clinical responders. At W2, fM2-PK, fLact and fCal levels predicted accurately the response to IFX induction. At W14, fLact, fCal, and fM2-PK were individually reliable markers to predict sustained response at W52. The performances of fNeo and fZon were weaker in this setting.

## Conclusions

The performance of fM2-PK at W2 to predict response to induction therapy with IFX was superior to that of fLact and fCal, whereas monitoring fLact was the best tool to predict adequately the course of the disease at one year under maintenance IFX in UC.



## Keywords

Fecal markers; Response to infliximab; Ulcerative colitis

Recommended articles Citing articles (15)

These authors contributed equally to the study.

View full text

© 2016 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.



About ScienceDirect

Remote access

Shopping cart

Advertise

Contact and support

Terms and conditions

Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookies**. Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

